The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Taryn Robertson, a professor at Randolph College, is currently fundraising and training to run a marathon for her father who ...

Michael J. Fox appears to be heading back to the future — at least when it comes to putting his memories of the popular film ...

A Tampa woman rang in her 50th birthday with a 150-mile bike ride around Davis Islands with her cycling friends. The ride ...

Jan. 14, 2025 — There may be a link between hearing impairment and an increased risk of developing Parkinson's according to new research. This is one of the first studies to examine whether ...

London, has collaborated with the London-based advocacy group Parkinson's In Motion and The Michael J. Fox Foundation (MJFF) ...

A new study by researchers at Ireland's Maynooth University, based on patient data gathered by the US-based Michael J. Fox ...